Shares in the spin-out have risen by a quarter on announcement of its latest trial results.
Aerie Pharmaceuticals, a Duke University spin-out, is approaching a major success. The company has reported successful results in a Phase 2b trial for a therapy against glaucoma.
The company’s shares jumped 25% on announcement, and traded for $26.37. The company was incorporated in 2005 and only went public in October 2013 in a $67.2m IPO.
Dubbed Roclatan, the once-daily eyedrop therapy was tested in 297 patients over 28 days, and was proven to be more efficient than the currently prescribed…
